Roche and MorphoSys go pivotal with early Alzheimer's drug
This article was originally published in Scrip
Executive Summary
Roche has expanded the ongoing Phase II SCarlet RoAD trial investigating the fully human anti-amyloid, monoclonal antibody, gantenerumab, for prodromal (early) Alzheimer's disease to what could be 'a potentially pivotal Phase II/III study'.